



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: NRG-DT001 Study Chair
Meng Welliver, MD, PhD

DATE: February 21, 2020

RE: PROTOCOL NRG-DT001 – Cohort B (Dose level 1): Temporarily Closed to Accrual

Cohort B (Dose Level 1) Temporarily Closed to Accrual

Cohort B (abdomen/pelvis/retroperitoneum) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” is temporarily closed to accrual effectively immediately because it has reached its protocol-specified accrual target.

Cohort B will remain temporarily closed for approximately 2 months until all patients complete the DLT evaluation period. NRG Oncology will send a broadcast with more details regarding reopening when all patients have completed the DLT evaluation period.

Note: Dose level 3 for cohort A (extremity/body wall) remains open to accrual.

Please distribute this information to the appropriate personnel.

A handwritten signature in blue ink that reads "Meng Welliver".

Meng Welliver, MD, PhD